TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05622461

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Road-to-recovery
Description: R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Road-to-recovery
Description: R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
Study: NCT05624411

Intervention type: DEVICE
Intervention: CU T380A IUD
Description: post-placental insertion of intrauterine contraceptive device

Intervention type: DEVICE
Intervention: multiload 375 IUD
Description: post-placental insertion of intrauterine contraceptive device
Study: NCT05364476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16 weeks digital intervention
Description: Participants will be enrolled into a 16-week program which consist of an online and offline support from health coaches and dietitian. Participants will be given diet and exercise recommendations and lesson plans on a weekly basis by the health coaches, and supported by the dietitian.~Participants will be required to log in their blood sugar levels, weight and steps daily using connected device, including glucometer, smart band and body fat weighing scale provided into the daily report card. They will also be required to manually record their meals and exercise daily in the daily report card provided upon enrollment into study. Reviews of log will be done on a weekly/biweekly interval by the health coaches.
Study: NCT05028309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical unloading of the Thorax using an external cuirass
Description: External cuirass (i.e., a plastic shell over the thorax) will be used to mechanically unload the chest wall. The cuirass has different operating modes. It can generate a constant negative pressure over the chest wall (e.g., -20cmH2O) or it can be triggered off mouth flow so it can generate a negative pressure on the chest wall during inspiration (e.g., -21cmH2O) and a positive pressure during expiration (e.g., +7cmH2O).
Study: NCT05924659

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cerabral training
Description: 1 week of cerebral training (neurofeedback or sham)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerabral training
Description: 1 week of cerebral training (neurofeedback or sham)
Study: NCT05235360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affect imagery
Description: Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
Study: NCT06437951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan Injection
Description: 20/40/80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fexuprazan Injection placebo
Description: 20/40/80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan Injection_part 2
Description: 20mg
Study: NCT05235360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affect imagery
Description: Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affect imagery
Description: Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
Study: NCT06437951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexuprazan Injection_part 3
Description: 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan Injection_part 3
Description: 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexuprazan tablet
Description: 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan tablet
Description: 40mg
Study: NCT04643483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive adalimumab in a pre-specified sequence during the Treatment Periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods.
Study: NCT06022341

Intervention type: OTHER
Group type: OTHER
Intervention: Multiomic characterization
Description: Multiomics analysis include targeted-NGS with a 400-genes panel, RNA-seq and methylome. All the genomic libraries will be constructed at the genomic facility of Angers University Hospital and the sequencing will be performed on a NovaSeq6000 in the GenoBIRD Platform in Nantes. Bioinformatic analysis will be performed and will derive for each sample: SNV/Indel and CNV from DNA sequencing, expression of mRNA and lncRNA, genes fusion and splicing events from RNA-seq, and methylation beta-values from methylome.

Intervention type: OTHER
Group type: OTHER
Intervention: In vitro drug screening
Description: The drug screening will be performed on the 'NEXT-AML' platform at St-Louis Hospital, Paris. This platform uses a multiparametric screening strategy based on flow cytometry measurements of cell viability, cell differentiation and stem cell compartment. Primary patient cells will be cultured in a specific niche-like medium with amino-acids, cytokines and stromal cells (Dal Bello et al. 2022). Twenty-five drugs at 6 concentrations covering a 1000-fold concentration range will be studied for each sample.
Study: NCT06045715

Intervention type: OTHER
Intervention: follow-up with different time intervals
Description: After radical surgery, patients are followed up with different time intervals
Study: NCT06276010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nafamostat mesilate
Description: Use nafamostat mesilate as an anticoagulant

Intervention type: DRUG
Group type: OTHER
Intervention: unfractionated heparin group
Description: Use unfractionated heparin as an anticoagulant
Study: NCT05235360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral imagery
Description: Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral imagery
Description: Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral imagery
Description: Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).
Study: NCT05521243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beam Organics Dream Powder
Description: The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beam Organics Dream Powder Extra Strength
Description: The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
Study: NCT05235360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral imagery
Description: Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral imagery
Description: Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.
Study: NCT04848636

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Sodium and Proton MRI
Description: Sodium-23 MRI of the Heart Proton MRI of the Heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Sodium and Proton MRI
Description: Sodium-23 MRI of the Heart Proton MRI of the Heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Sodium and Proton MRI
Description: Sodium-23 MRI of the Heart Proton MRI of the Heart
Study: NCT05449171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D
Description: Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
Study: NCT05521243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The main ingredients in the placebo are:~Coconut milk powder, cocoa, cinnamon, monk fruit, natural vanilla flavor

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The main ingredients in the placebo are:~Coconut milk powder, cocoa, cinnamon, monk fruit, natural vanilla flavor
Study: NCT06158932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement
Description: This product contains Myo-Inositol, D-Chiro-Inositol, Folate and Vitamin D.
Study: NCT06309992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Survodutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching survodutide
Study: NCT05968430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat
Description: Tablet, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat
Description: Tablet, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat
Description: Tablet, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, administered orally
Study: NCT04294641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 140 mg capsules for a dose of 420 mg daily by mouth for up to 12 months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: At screening.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PFT's
Description: Participants should have PFTs if not performed ≤3 months prior to start of study treatment and Cycle 7, Day 1 (6 months).~Optional at Cycle 12, Day 28 (12 months) and Cycle 24, Day 28 (24 months).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Non-contrast CT at baseline and later during the study if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid pulse (prednisone)
Description: 0.5-2mg/kg/day allowed for clinical disease stabilization during first 4 weeks after starting Ibrutinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: At any dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: As clinically indicated. At doses less than or equal to suspension 200 mg twice a day (BID) if ibrutinib dose modified to 280 mg once daily.~OR Posaconazole suspension 200 mg three times a day (TID) or 400 mg BID if Ibrutinib dose modified to 140 mg once daily.~OR Posaconazole injection intravenous (IV) injection 300 mg once daily; or delayed-release capsules 300 mg once daily if Ibrutinib dose modified to 140 mg once daily..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Treat or prevent bronchiolitis obliterans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Treat or prevent bronchiolitis obliterans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Neutrophil growth factor permitted per institutional policy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Neutrophil growth factor permitted per institutional policy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Red cell growth factor permitted per institutional policy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusions
Description: According to institutional policy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral/Skin biopsy
Description: Optional. Baseline, Cycle 7, Day 1 (6 months), Cycle 12, Day 28 (12 months) and Cycle 24, Day 28.
Study: NCT05752461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2004 injection
Description: low dose subcutaneous injection once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2004 injection
Description: medium dose subcutaneous injection once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2004 injection
Description: high dose subcutaneous injection once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium injection
Description: 40 mg administered as subcutaneous injection once daily
Study: NCT05888480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The end-of-life communication skills training
Description: Training methods include lectures, video demonstrations, and simulation in small groups (4-5 trainees per group with multidisciplinary roles). Written and audiovisual learning materials will be offered. Each session will be 150 minutes, including lectures and video demonstration (90 min/session) and simulation and feedback (60 min/session). One session will be conducted in two weeks. Totally there will be four sessions completed in 8 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine training activity
Description: Routine training activities arranged by relevant departments in hospitals
Study: NCT05662202

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BF-200 ALA and red light LED lamp
Description: Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle and red light LED lamp
Description: Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit.
Study: NCT06333678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: 10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: 960 mg, Patients who do not tolerate sotorasib at 960 mg can be dose reduced to 120 mg.
Study: NCT04554602

Intervention type: DIAGNOSTIC_TEST
Intervention: Fusion ultrasound
Description: Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fusion ultrasound
Description: Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
Study: NCT06133998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incentive spirometer with aerobic exercises
Description: Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung. This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: incentive spirometry without aerobic exercises
Description: Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~* In aerobic exercise following treatment protocol will be involve~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire.~* We will check the chest expansion by measuring tap.